Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, stem-cell technology specialist Cytori Therapeutics (NASDAQ:CYTX) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Cytori's business and see what CAPS investors are saying about the stock right now.

Cytori facts

Headquarters (Founded)

San Diego (1996)

Market Cap

$299 million

Industry

Biotechnology

Trailing-12-Month Revenue

$14 million

Management

Co-Founder/CEO Christopher Calhoun
CFO Mark Saad

Trailing-12-Month Return on Assets

(40.8%)

Cash / Debt

$13 million / $6 million

3-Month Return

132%

Highly Rated Biotech Alternatives

Amgen (NASDAQ:AMGN)
Celgene (NASDAQ:CELG)
Gilead Sciences (NASDAQ:GILD)

CAPS Members Bearish on CYTX Also Bearish on

Targacept (NASDAQ:TRGT)

CAPS Members Bullish on CYTX Also Bullish on

Geron (NASDAQ:GERN)
Bank of America (NYSE:BAC)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 57% of the 79 All-Star members who have rated Cytori believe the stock will underperform the S&P 500 going forward. These bears include gokylego and TSIF.

Just last week, gokylego tapped Cytori as a former four-star stock gone too wild: "Too high of a bounce too soon. Money is safer elsewhere."

In a pitch from three days ago, TSIF echoes that bearishness. Here's an excerpt:

Biopharmaceuticals rarely pan out, even those who get FDA approval and produce an actual product. While Cytori has been successful in getting products to market, similar to others, ... the share price spikes above actual revenue opportunities as trial data is released and FDA approval nears or is even granted as in Cytori's case. ...

Cytori's stem cell work is also not unique. ... While they are international in products and devices for procedures that have recurring revenue, Cytori has net tangible book value of NEGATIVE $6 Million and a market cap of $300 Million. ... Only by multiple stock issues have they remained solvent. Even if they produce a product that lives up to the market hype, the share count will not generate a meaningful EPS.

What do you think about Cytori, or any other stock for that matter? If you want to retire rich, you need to protect your portfolio from any undue risk. Staying away from dangerous stocks is crucial to securing your financial future, and on Motley Fool CAPS, thousands of investors are working every day to flag them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool's disclosure policy always gets a perfect score.